Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ ...

JPMorgan raised the firm’s price target on Zai Lab (ZLAB) to $51 from $44 and keeps an Overweight rating on the shares. The firm updated models ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zai Lab (ZLAB – Research Report), Perspective ...

Zai Lab (ZLAB – Research Report) received a Buy rating and a $55.00 price target from Scotiabank analyst Louise Chen today. The company’s shares opened today at $35.16. See what stocks are ...

Scotiabank initiated coverage of Zai Lab (ZLAB) with an Outperform rating and $55 price target The firm says that although geopolitical risk has capped the stock’s upside for years, Zai Lab is ...

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, tisotumab vedotin-tftv, for the treatment of patients ...

Shares of ZLAB stock opened at $38.20 on Thursday. Zai Lab has a 1 year low of $13.48 and a 1 year high of $39.61. The stock’s 50 day simple moving average is $29.47 and its two-hundred day ...